IDEAYA Biosciences, Inc. (NASDAQ: IDYA)

IDEAYA Biosciences, Inc., a company specializing in precision medicine oncology, is publicly traded on the NASDAQ exchange under the symbol IDYA. With a focus on discovering and developing targeted therapeutics for patient populations selected using molecular diagnostics, IDEAYA operates in the oncology sector, specifically targeting genetic alterations in cancer cells.

IDEAYA's primary business activities revolve around the discovery and development of small molecule inhibitors of protein kinases and other targets in DNA damage repair pathways or tumor metabolism pathways. The company's product pipeline includes darovasertib, IDE397, IDE161, and GSK101, all in various stages of clinical development. Darovasertib, a small molecule inhibitor of protein kinase C (PKC), is being developed for the treatment of uveal melanoma, a type of eye cancer. IDE397, a small molecule inhibitor of methionine adenosyltransferase 2A (MAT2A), is targeted at solid tumors with MAT2A gene deletion. IDE161, a small molecule inhibitor of poly (ADP-ribose) glycohydrolase (PARG), is being developed for the treatment of solid tumors with homologous recombination deficiency (HRD). GSK101, a small molecule inhibitor of Pol Theta helicase, is being developed for the treatment of patients with tumors with BRCA or other HRD.

IDEAYA is a pioneering company in the precision medicine oncology space, and its competitive advantages include its expertise in small molecule drug discovery and its ability to identify and validate new targets and biomarkers for patient selection. This focus on precision medicine allows the company to select patient populations for its clinical trials, providing a further competitive advantage.

The company's customer base includes leading pharmaceutical companies such as Pfizer, Amgen, and Gilead Sciences, with whom IDEAYA has established collaborations to support its clinical development activities. These collaborations include supply agreements for crizotinib, a drug used in combination with darovasertib in IDEAYA's clinical trials.

IDEAYA's product portfolio includes darovasertib, IDE397, IDE161, and GSK101, all in various stages of clinical development. These products are being developed for the treatment of various types of cancer, including uveal melanoma, solid tumors, and tumors with homologous recombination deficiency. The company's regulatory strategy includes evaluation of potential clinical endpoints such as vision and organ preservation, which could enable a discussion with regulatory authorities on an accelerated approval pathway.